Takeda

We follow the science, to unlock innovation and pursue sustainable answers. We are guided by our commitment to patients, our people and the planet. Our vision is to deliver life-transforming treatments to those in need. We are steadfast in our purpose for better health for people and a brighter future for the world.

Treating cancer is incredibly complex and #ChronicMyeloidLeukemia (CML) has been historically challenging to treat due to several factors. Today, Takeda announced an option agreement with Ascentage Pharma that will allow us to enter into a future exclusive global license agreement for its investigational therapy currently in development for CML and other #HematologicalCancers. Learn more here: https://lnkd.in/etq95HxF

This #WorldBloodDonorDay, we honor and celebrate the millions of individuals who donate plasma at our BioLife Plasma Services centers. Your donations are essential in helping us address the growing patient need for plasma-derived therapies around the world. If you’re looking for a way to help others, consider becoming a #plasmadonor today.

We are continuing to invest in our over 70 years of expertise at our Los Angeles plasma-derived therapies production site to better serve patients. We are expanding our plasma fractionation capabilities enabling us to serve more patients with rare, chronic and genetic diseases, such as #Immunodeficiencies and #BleedingDisorders. Learn how you could become part of our team: https://lnkd.in/enhkrqDJ #PatientCommitment #Sustainability #PlasmaDerivedTherapy

From physicians to patients to our employees, people across Brazil have stories to share about their experience with dengue. But a coordinated effort can help reduce the burden of disease. Watch them tell their stories. https://lnkd.in/emh_xPrf

We’re joining the International Society For Neglected Tropical Diseases (ISNTD) and the wider global dengue community in recognizing the upcoming #WorldDengueDay. We stand united in the fight against the threat of dengue globally. Together with patients, researchers, companies and organizations worldwide, we are committed to raising awareness to help reduce the impact of this mosquito-borne disease and highlighting the importance of a day devoted to dengue awareness. According to the WHO, in 2023 alone, dengue led to a record-breaking total of over 6.5 million cases worldwide. Now, more than ever, we need to gather in our efforts to create a future free from dengue burdens. To learn more about World Dengue Day and dengue’s global impact, visit our dengue educational website: https://lnkd.in/eBbu7xWi

As a global values-based, R&D-driven biopharmaceutical company, we have been putting patients at the center of everything we do for more than 240 years. Our data, digital and technology (DD&T) strategy, deeply rooted in our long-standing values, is central to how we deliver on our commitments to patients and communities. Recently our CFO, Milano Furuta visited our Innovation Capbility Center (ICC) in Bratislava, Slovakia, as well as our Takeda Business Solutions (TBS) Hub in Łódź, Poland. These visits highlighted the great potential of both ICC and TBS. The ICCs function as our “digital factories”, leveraging our internal capabilities to deliver data and digital solutions at scale. TBS is the business solutions arm of Takeda, streamlining processes across HR, finance, and procurement. We are committed to incorporating DD&T across our entire value chain and look forward to witnessing our teams’ advancement as we strive to develop and deliver medicines to patients more efficiently. Check out new opportunities at ICCs to embark on a purposeful career journey delivering digital solutions that improve patients‘ lives: https://lnkd.in/erHYgagM #iccslovakia #TBS #innovation

Today on Founder's Day, we celebrate and reflect on 243 years of our unwavering philosophy - to work with integrity and always put patients first. From 1781 to today, we discover and deliver life-transforming treatments, guided by our values and our commitment to patients, our people and the planet.

#TeamTakeda will be onsite at the EULAR - European Alliance of Associations for Rheumatology Congress in Vienna. We are eager to collaborate and exchange ideas with our peers on the latest challenges and advancements in rheumatology. Join us onsite at booth S12 to learn more about our commitment to #PsoriaticArthritis. #EULAR2024 This information is intended for EULAR 2024 congress attendees only. Takeda does not have any approved treatment for psoriatic arthritis.

People living with hematological malignancies, or blood cancers, are at high risk of developing an immune deficit, a result of which can be low antibody levels – also known as secondary immunodeficiency (SID). This condition leaves them vulnerable to infections that can lead to hospitalization or even death. At this year’s European Hematology Association (EHA) meeting, Takeda is working to raise awareness of this risk, including hosting a symposium on infection management for patients with hematological cancers featuring renowned experts Hans Lee, Niels van de Donk and Silvia Sánchez-Ramón. By raising awareness on how to recognize and manage SID, we want to ensure patients and their doctors can focus on treating what is most important – their cancer. #CARTtherapy #bispecificantibodies #multiplemyeloma #CLL #immunology #cancertreatment #hematooncology #infectionmanagement #earlydetection #secondaryimmunodeficiency #SID #PlasmaDerivedTherapies #EHA